-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Reschedules NeOnc Technologies' End-of-Phase 1 Meeting on NEO212

PUBT·11/19/2026 18:40:08
Diffusion vocale
FDA Reschedules NeOnc Technologies' End-of-Phase 1 Meeting on NEO212
  • NeOnc's FDA end-of-Phase 1 meeting on NEO212 was rescheduled to Nov. 23, 2026, from Nov. 17, 2026.
  • The company will seek feedback on Phase 2 trial plans and potential regulatory pathways for the oral CNS cancer treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611191337PRIMZONEFULLFEED9881649) on November 19, 2026, and is solely responsible for the information contained therein.